Results 121 to 130 of about 78,600 (311)

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence

Therapeutics and Clinical Risk Management, 2020
Silvia Linari, Giancarlo Castaman Department of Oncology, Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, ItalyCorrespondence: Giancarlo CastamanDepartment of Oncology, Center for Bleeding Disorders and Coagulation ...
Linari S, Castaman G
doaj  

Hemophilia B in a Pair of Monozygotic Negro Twins [PDF]

, 1964
Israel Roisenberg
openalex   +1 more source

F8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Background Neutralising antibodies (inhibitors) against factor VIII can result in severe bleeding in persons with nonsevere haemophilia A (NSHA). The INSIGHT study of 1112 persons with NSHA in a predominantly White population identified 19 different F8 missense variants that were associated with inhibitor development. Objective To describe the
Ming Y. Lim, Kristy Lee, Jill M. Johnsen, Nigel S. Key   +3 more
wiley   +1 more source

Evaluation of Safety and Efficacy of Emicizumab Prophylaxis in Egyptian Pediatric Patients with Hemophilia A

Turkish Journal of Hematology
Objective: Hemophilia A (HA) is a hereditary X-linked bleeding disorder secondary to deficiency of the clotting factor VIII (FVIII). Emicizumab is a monoclonal antibody that replaces the function of the activated FVIII and prevents bleeding in HA ...
Tamer Hassan, Marwa Zakaria, Manar Fathy, Ahmed Farag, Eman Abdelhady, Dalia Gameil, Mustafa Abu Hashem   +6 more
doaj   +1 more source

Current Studies in Hemophilia [PDF]

, 1967
G. I. C. Ingram
openalex   +1 more source

Measurement of the Effectiveness of (AHG) Therapy in Hemophilia [PDF]

, 1963
J A Penner
openalex   +1 more source

INDUCTION OF TOLERANCE BY ORAL ADMINISTRATION OF FACTOR VIII AND TREATMENT OF HEMOPHILA [PDF]

, 2011
Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a Subject a therapeutically effective amount of the deficient anti gen, wherein the antigen is not present in a liposome.
Alpan, Oral, Kamala, Tirumalai, Matzinger, Polly, Velander, William Hugold   +3 more
core   +1 more source

The Trust‐Link Relational Transition Model: A Unitary Caring Framework for Youth With HIV Transitioning to Adult Healthcare

Journal of Advanced Nursing, EarlyView.
ABSTRACT Aims To develop a conceptual model integrating Robinson's Theory of Trust and Watson's Caritas Processes to guide trust‐building approaches and caring practices that support adolescents and young adults with HIV during the healthcare transition from paediatric to adult care.
Emily Anne Barr, Sara Horton‐Deutsch
wiley   +1 more source

AN ASSESSMENT OF KNOWLEDGE AND ATTITUDES OF GENETIC COUNSELING SERVICES IN U.S. HTCs [PDF]

, 2013
Hemophilia is a hereditary bleeding disorder which requires lifelong specialized care. A network of Hemophilia Treatment Centers (HTCs) exists to meet the medical needs of patients affected by hemophilia.
Brown, Deborah, Escobar, Miguel, Hashmi, Syed, M.D., Ph.D, Khleif, Aroub Ayham, Noblin, Sarah, Raia, Marianna, Rolf, Brad   +6 more
core  

Characterization and management of patients with hereditary factor X deficiency: A case series

Transfusion, EarlyView.
Abstract Background Hereditary factor X deficiency (HFXD) is an ultra‐rare, autosomal recessive bleeding disorder that results in reduced factor X coagulant activity (FX:C). HFXD is traditionally classified by severity as severe (FX:C <1%), moderate (FX:C = 1%–5%), or mild (FX:C = 6%–10%).
Meera Chitlur, Lauren E. Amos, Mark T. Reding, Cynthia Sabo, Suchitra S. Acharya   +4 more
wiley   +1 more source